Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Eich, Hans Theodor  [Clear All Filters]
2024
Rosenbrock J, Kaul H, Oertel M, Celik E, Linde P, Fan J, Eichenauer DA, Broeckelmann PJ, von Tresckow B, Kobe C, et al. Involved-site radiotherapy is equally effective and less toxic than Involved-field radiotherapy in patients receiving combined modality treatment for early-stage unfavorable Hodgkin lymphoma - an analysis of the randomized phase III HD17 trial of the Germ. Int J Radiat Oncol Biol Phys. 2024.
2023
Haiduk TS, Sicking M, Brücksken KA, Espinoza-Sánchez NA, Eder KMoritz, Kemper B, Eich HTheodor, Götte M, Greve B, Troschel FM. Dysregulated Stem Cell Markers Musashi-1 and Musashi-2 are Associated with Therapy Resistance in Inflammatory Breast Cancer. Arch Med Res. 2023;54(6):102855.
2022
Krautschneider SLennard, Troschel FM, Vadillo E, Eich HTheodor, Götte M, Espinoza-Sánchez NAdriana, Greve B. Enzymatic Digestion of Cell-surface Heparan Sulfate Alters the Radiation Response in Triple-negative Breast Cancer Cells. Arch Med Res. 2022.
Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, van den Berg H, Hassenpflug W, Raciborska A, Ek T, et al. High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. J Clin Oncol. 2022:JCO2101942.
2018
Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HTheodor, Götte M, Greve B. miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumour Biol. 2018;40(8):1010428318791887.
2013
Ibrahim SA, Hassan H, Vilardo L, Kumar SKatakam, Kumar AVijaya, Kelsch R, Schneider C, Kiesel L, Eich HTheodor, Zucchi I, et al. Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling. PLoS One. 2013;8(12):e85737.